Nurtec ODT (rimegepant ODT) / Pfizer, Eisai - LARVOL DELTA

Study on the Neoadjuvant Therapy of NSCLC with Chronic Pain Using Remeglitazone Combined with Immunochemotherapy (ChiCTR) - P=N/A | N=12 | Not yet recruiting | Sponsor: Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pain • Solid Tumor

Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

New P1 trial • Oncology • Solid Tumor • Urothelial Cancer

Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov) - P2 | N=220 | Not yet recruiting | Sponsor: Shanghai Zhongshan Hospital

New P2 trial • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Healthcare providers' perceptions and prescribing behaviors of short-term prevention treatment of migraine in the United States. (PubMed, Pain Manag) - "Gepants were the most frequently prescribed STP treatment (71.9%), with rimegepant being the most prescribed gepant for STP (84.1%)...HCPs aware of STP believe patients with migraine, especially those with perimenstrual attacks, may benefit from STP treatment. Gepants were the most prescribed STP migraine treatment."

Journal • CNS Disorders • Migraine • Pain

CORRELATE-UK: Consistency of Response With Rimegepant in Acute Treatment of Migraine (clinicaltrials.gov) - P=N/A | N=250 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Jul 2026 ➔ Oct 2026 | Trial primary completion date: Jul 2026 ➔ Oct 2026

Trial completion date • Trial primary completion date • CNS Disorders • Migraine

BioM: Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Nordlandssykehuset HF

New trial • CNS Disorders • Migraine

A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Migraine

Drugs for acute treatment of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Drugs for prevention of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Calcitonin gene-related peptide promotes mast cell-mediated neuroimmune inflammation through the CALCRL/RAMP1-JAK3-STAT1 axis in rosacea. (PubMed, Front Immunol) - "Rimegepant or ritlecitinib attenuated CGRP-induced JAK3-STAT1 activation and mast-cell responses. These findings identify a CGRP-associated neuroimmune pathway in rosacea in which CALCRL/RAMP1-linked JAK3-STAT1 signaling promotes mast cell-mediated inflammatory amplification. Targeting the CGRP-CALCRL/RAMP1-JAK3-STAT1 axis may provide a mechanism-based therapeutic strategy for neurovascular-dominant or treatment-refractory rosacea."

Journal • Dermatology • Inflammation • Rosacea • CALCRL • JAK3 • KIT • STAT1

Comparison table: Some drugs for migraine prevention. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

The Remote Electrical Neuromodulation (REN) wearable reduces medication use for the treatment of chronic pain in migraine patients (PAINWeek 2026) - "Medication types included three categories that were presented to patients using commercial drug names: (1) over-the-counter (OTC; e.g. Advil, Excedrin, Tylenol), (2) first-line prescribed medications including oral triptans (e.g. Imitrex, Maxalt, Relpax) and oral medication for nausea (e.g. Zofran, Reglan, Compazine), (3) second-line prescribed medications including nasal/injectable triptans (e.g. Tosymara, Onzetra, Zembrace, Zoming) and branded new generation medications (Reyvow, Nurtec, and Ubrelvy). Data from 31,516 migraine patients who conducted 148,705 REN treatments were analyzed. Treatment-level analysis showed that 71.1% of the treatments were performed without the use of any prescribed medications (50.6% REN alone, 14.4% REN + OTC meds), while 28.9% were conducted in conjunction with first- or second-line prescribed medications. A patient-level analysis looked at a subset of 2,653 patients who performed at least 10 REN treatments each, in which they reported..."

Clinical • CNS Disorders • Migraine • Pain

Chronic Migraine Remission with Combination of Remote Electrical Neuromodulation (REN) and In-Clinic / Patient-Administered Sphenopalatine Ganglion (SPG) Block (PAINWeek 2026) - "Current acute treatments included rizatriptan, ubrogepant and acetaminophen with recent discontinued acute therapies including rimegepant and NSAIDS. Current preventative treatments include onabotulinumtoxinA, galcanezumab, amitriptyline, cyclobenzaprine, ondansetron and occipital nerve blocks with recent discontinued preventatives including topiramate... Patient was seen weekly for initial treatment sequence and noted near complete resolution of acute migraine symptoms after the first in-clinic SPG administration with smaller, although noticeable, levels of relief with self-administered SPG administration. Patient also noted significant, although not complete, reduction of acute pain and nausea within the first week of initiating REN. After one month of treatment, patient noted that migraine frequency reduced to one episode per week from the previous 4 to 6 episodes and was able to manage most acute episodes with acetaminophen, with rare need for other acute..."

Clinical • CNS Disorders • Depression • Migraine

2026 Taiwan guidelines for the acute pharmacologic treatment of migraine in adults. (PubMed, J Chin Med Assoc) - "Non-specific agents include acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs: diclofenac, ibuprofen, naproxen). Injectable prochlorperazine is also strongly recommended. Ergotamine/caffeine combinations are less effective and are second-line agents, while high-dose aspirin is limited by gastrointestinal risk. Considering the potential risk of dependency, tramadol or tramadol/paracetamol combinations should be reserved until all other agents fail, and should be limited to oral forms. Other opioids, such as morphine, butorphanol, etc., lack evidence and are not recommended...Acetaminophen remains first-line for children and pregnant women. To prevent medication-overuse headache, acute treatments, including NSAIDs, acetaminophen, triptans, ergot derivatives, and combination analgesics, should not exceed two days per week, probably with the exception of rimegepant."

Journal • Addiction (Opioid and Alcohol) • Cardiovascular • CNS Disorders • Migraine • Pain

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. (PubMed, Headache) - "This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine."

Journal • CNS Disorders • Migraine • Pain

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. (PubMed, Neurology) - "This SR provides a comprehensive synthesis of evidence on pharmacologic migraine prevention in adults. High- and moderate-confidence findings confirm the efficacy of several established and newer preventive therapies and demonstrate improvements in patient-reported outcomes across multiple validated measures. These conclusions informed the development of evidence-based recommendations, presented in a companion publication, to guide clinicians in selecting preventive medications for adults with episodic and chronic migraine."

Journal • Review • CNS Disorders • Migraine • Pain

Effectiveness of Rimegepant for the Acute Treatment of Migraine Among Participants Using Different Types of Preventive Therapy: Analyses from CONFIDENCE. (PubMed, Neurol Ther) - P | "High rates of meaningful pain relief, meaningful improvement in function, and treatment satisfaction were observed with rimegepant for the acute treatment of migraine when used alongside different types of preventive medication in the real world."

Journal • CNS Disorders • Migraine • Pain

Ildong Pharmaceutical said Tuesday that it has signed a distribution and co-promotion agreement with Pfizer Korea for Nurtec orally disintegrating tablets (ODT), a novel migraine treatment containing rimegepant. (Korea Biomedical Review) - "Under the agreement, Ildong Pharmaceutical will handle distribution of Nurtec ODT in Korea, while the two companies will begin joint promotional activities this month."

Commercial • Migraine

PRAC adopted updates to sections 4.2, 4.4, 4.8 and 5.1 of the SmPC to introduce a daily dosing regimen for migraine prophylaxis, revise the warning on medication-overuse headache, and incorporate clinical safety and efficacy data from studies C4951010 and C4951011. (European Medicines Agency) - Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of meeting on 8 – 11 Jun 2026: The Package Leaflet was updated accordingly, and RMP version 1.1 was submitted. [AI generated summary]

PRAC • Migraine

Pfizer Korea has launched Nurtec ODT (rimegepant sulfate hydrate), Korea’s first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for both acute migraine treatment and prevention of episodic migraine in adults. (Korea Biomedical Review)

Launch non-US • Migraine

Rimegepant For Endometriosis Pain (clinicaltrials.gov) - P2 | N=132 | Not yet recruiting | Sponsor: Mayo Clinic

New P2 trial • Endometriosis • Gynecology • Pain • Women's Health

Rimegepant, wenn Triptan nicht möglich? (PubMed, MMW Fortschr Med) - No abstract available

Journal • Review

Baseline severity is not treatment timing in acute rimegepant treatment for vestibular migraine. (PubMed, Cephalalgia) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Reply to: Baseline severity is not treatment timing in acute rimegepant treatment for vestibular migraine. (PubMed, Cephalalgia) - No abstract available

Journal • CNS Disorders • Migraine • Pain

A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Migraine